Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System

Gels, Journal Year: 2022, Volume and Issue: 8(2), P. 82 - 82

Published: Jan. 28, 2022

Drug instillation via a topical route is preferred since it desirable and convenient due to the noninvasive easy drug access different segments of eye for treatment ocular ailments. The low dose, rapid onset action, or no toxicity local tissues, constrained systemic outreach are more prevalent in this route. majority ophthalmic preparations market available as conventional drops, which rendered <5% instilled eye. poor availability tissue may be attributed physiological barriers associated with cornea, conjunctiva, lachrymal drainage, tear turnover, blood-retinal barrier, enzymatic degradation, reflex thus impeding deeper penetration cavity, including posterior segment. static composed sclera, retina, whereas dynamic barriers, referred conjunctival choroidal blood flow, dilution, lymphatic clearance, critically impact bioavailability drugs. To circumvent such rational design therapeutic system indeed required enriching holding time permeation drug, overall improve tissue. This review provides brief insight into structural components well challenges current developments arena system, based on novel delivery systems nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, situ gel, dendrimers, contact lenses, implants, microneedles. These nanotechnology platforms generously evolved overwhelm troubles controlled-drug-formulation-based strategic approach has considerable potential enrich concentration specific area

Language: Английский

---

Nanotechnology-based ocular drug delivery systems: recent advances and future prospects

Journal of Nanobiotechnology, Journal Year: 2023, Volume and Issue: 21(1)

Published: July 22, 2023

Abstract Ocular drug delivery has constantly challenged ophthalmologists and scientists due to various anatomical physiological barriers. Static dynamic ocular barriers prevent the entry of exogenous substances impede therapeutic agents' active absorption. This review elaborates on anatomy eye associated constraints. Followed by an illustration some common diseases, including glaucoma their current clinical therapies, emphasizing significance therapy in treating diseases. Subsequently, advances modalities, especially nanotechnology-based systems, are recommended, typical research is highlighted. Based related research, systematic comprehensive characterizations nanocarriers summarized, hoping assist with future research. Besides, we summarize ophthalmic drugs currently market or still trials recent patents nanocarriers. Finally, inspired trends concepts, provide insight into challenges faced novel systems further put forward directions for We hope this can inspiration motivation better design development formulations. Graphical abstract

Language: Английский

---

Microneedles for advanced ocular drug delivery

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 201, P. 115082 - 115082

Published: Sept. 9, 2023

In the field of ocular drug delivery, topical delivery remains most common treatment option for managing anterior segment diseases, whileintraocular injectionsare current gold standard treating posterior diseases. Nonetheless, eye drops are associated with low bioavailability (<5%), and theintravitreal administration procedure is highly invasive, yielding poor patient acceptability. both cases, frequent currently required. As a result, there clear unmet need sustained to eye, particularly in manner that can be localised. Microneedles, which patches containing an array micron-scale needles (<1 mm), have potential meet this need. These platforms enable localised while enhancing penetration molecules through key barriers, thereby improving overall therapeutic outcomes. Moreover, minimally invasive microneedles applied could provide significant advantages over traditional intravitreal injections regarding Considering benefitsofthis novel system, review provides in-depth overviewofthe microneedle systems including types used therapeutics delivered. Notably, we outline discuss challenges clinical translation these offer opinions on factors should considered improve such transition from lab clinic.

Language: Английский

---

Overview of Recent Advances in Nano-Based Ocular Drug Delivery

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(20), P. 15352 - 15352

Published: Oct. 19, 2023

Ocular diseases profoundly impact patients’ vision and overall quality of life globally. However, effective ocular drug delivery presents formidable challenges within clinical pharmacology biomaterial science, primarily due to the intricate anatomical physiological barriers unique eye. In this comprehensive review, we aim shed light on features eye, emphasizing natural it administration. Our goal is provide a thorough overview various characteristics inherent each nano-based system. These encompass nanomicelles, nanoparticles, nanosuspensions, nanoemulsions, microemulsions, nanofibers, dendrimers, liposomes, niosomes, nanowafers, contact lenses, hydrogels, microneedles, innovative gene therapy approaches employing techniques. We delve into biology methodology these systems, introducing their applications over past decade. Furthermore, discuss advantages illuminated by recent studies. While systems for ophthalmic formulations are gaining increasing attention, further research imperative address potential safety toxicity concerns.

Language: Английский

---

Nanotherapy for Neural Retinal Regeneration

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 14, 2025

Retinal diseases can severely impair vision and even lead to blindness, posing significant threats both physical mental health. Physical retinal regenerative therapies are poised revolutionize the treatment of various disorders associated with blindness. However, these must overcome challenges posed by protective inner outer blood‒retinal barriers. Nanotechnology applications in ophthalmology have shown great potential addressing issue drug delivery eye. Moreover, nanotechnology-based therapeutics profound clinical impacts on retinopathy, particularly regeneration, thereby improving patient outcomes. Continuous advancements nanotechnology being applied regenerate lost or damaged eye tissues treat loss blindness caused degenerative diseases. These approaches be categorized into three main strategies: i) nanoparticles for delivering drugs, genes, other essential substances; ii) nanoscaffolds providing biocompatible support; iii) nanocomposites enhancing functionality primary stem cells. The aim this comprehensive review is present current understanding a focus perspective functions nanomaterials.

Language: Английский

---

Ocular Nanomedicine

Advanced Science, Journal Year: 2022, Volume and Issue: 9(15)

Published: Feb. 12, 2022

Abstract Intrinsic shortcomings associated with conventional therapeutic strategies often compromise treatment efficacy in clinical ophthalmology, prompting the rapid development of versatile alternatives for satisfactory diagnostics and therapeutics. Given advances material science, nanochemistry, nanobiotechnology, a broad spectrum functional nanosystems has been explored to satisfy extensive requirements ophthalmologic applications. In present review, recent progress nanosystems, both emerging nanomaterials ophthalmology from state‐of‐the‐art studies, are comprehensively examined role their fundamental physicochemical properties bioavailability, tissue penetration, biodistribution, elimination after interacting microenvironment emphasized. Furthermore, along surface engineering nanomaterials, theranostic methodologies promoted as potential multipurpose ocular applications, such biomimetic (e.g., smart electrochemical eye), thus provoking holistic review “ocular nanomedicine.” By affording insight into challenges encountered by nanomedicine further highlighting direction future this provides an incentive enriching nanomedicine‐based research translation.

Language: Английский

---

Gene-Based Therapeutics for Inherited Retinal Diseases

Frontiers in Genetics, Journal Year: 2022, Volume and Issue: 12

Published: Jan. 7, 2022

Inherited retinal diseases (IRDs) are a heterogenous group of orphan eye that typically result from monogenic mutations and considered attractive targets for gene-based therapeutics. Following the approval an IRD gene replacement therapy Leber’s congenital amaurosis due to RPE65 mutations, there has been intensive international research effort identify optimal approaches range IRDs many now undergoing clinical trials. In this review we explore therapeutic challenges posed by current future may be applicable different subsets mutations. Emphasis is placed on five distinct have potential treat full spectrum IRDs: 1) using adeno-associated virus (AAV) nonviral delivery vectors, 2) genome editing via CRISPR/Cas9 system, 3) RNA endogenous exogenous ADAR, 4) mRNA targeting with antisense oligonucleotides knockdown splicing modification, 5) optogenetic aim replace function native photoreceptors engineering other cell types become capable phototransduction.

Language: Английский

---

Retinal Microenvironment‐Protected Rhein‐GFFYE Nanofibers Attenuate Retinal Ischemia‐Reperfusion Injury via Inhibiting Oxidative Stress and Regulating Microglial/Macrophage M1/M2 Polarization

Advanced Science, Journal Year: 2023, Volume and Issue: 10(30)

Published: Aug. 31, 2023

Retinal ischemia is involved in the occurrence and development of various eye diseases, including glaucoma, diabetic retinopathy, central retinal artery occlusion. To best our knowledge, few studies have reported self-assembling peptide natural products for suppression ocular inflammation oxidative stress. Herein, a GFFYE designed synthesized, which can transform non-hydrophilicity rhein into an amphiphilic sustained-release therapeutic agent, rhein-based nanofibers (abbreviated as Rh-GFFYE) are constructed treatment ischemia-reperfusion (RIR) injury. Rh-GFFYE significantly ameliorates stress vitro oxygen-glucose deprivation (OGD) model rat RIR also enhances electrophysiological recovery exhibits good biocompatibility. Importantly, promotes transition M1-type macrophages to M2 type, ultimately altering pro-inflammatory microenvironment. Further investigation mechanism indicates that activates PI3K/AKT/mTOR signaling pathway reduce inhibits NF-κB STAT3 pathways affect macrophage polarization. In conclusion, rhein-loaded nanoplatform alleviates injury by modulating The findings expected promote clinical application hydrophobic injury-associated diseases.

Language: Английский

---

A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 200, P. 115005 - 115005

Published: July 5, 2023

Language: Английский

---

Formulating Resveratrol and Melatonin Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) for Ocular Administration Using Design of Experiments

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(1), P. 125 - 125

Published: Jan. 18, 2024

Recent studies have demonstrated that Sirtuin-1 (SIRT-1)-activating molecules exert a protective role in degenerative ocular diseases. However, these hardly reach the back of eye due to poor solubility aqueous environments and low bioavailability after topical application on eye’s surface. Such hindrances, combined with stability issues, call for need innovative delivery strategies. Within this context, development self-nanoemulsifying drug systems (SNEDDS) SIRT-1 can represent promising approach. The aim work was design optimize SNEDDS two natural agonists, resveratrol (RSV) melatonin (MEL), potential implications treating diabetic retinopathy. Pre-formulation were performed by Design Experiment (DoE) approach construct ternary phase diagram. optimization carried out using Response Surface Methodology (RSM). Four types consisting different surfactants (Tween® 80, Tween® 20, Solutol® HS15, Cremophor® EL) optimized achieve best physico-chemical parameters application. Stability tests indicated produced 80 formulation preserved molecules, so it was, therefore, selected further technological studies. prepared Capryol® PGMC, Transcutol® P loaded RSV or MEL. evaluated other parameters, such as mean size (found be ˂50 nm), homogeneity (PDI < 0.2), emulsion time (around 40 s), transparency, content (>90%), mucoadhesion strength, vitro release, pH osmolarity, dilution, cloud point. Finally, an evaluation rabbit corneal epithelial cell line (SIRC) assess their cytocompatibility. overall results suggest used nanocarriers

Language: Английский

---